O'Neil Global Advisors’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

O'Neil Global Advisors’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-6,500	Closed	-$684K	–	75
2022 Q1	$684K	Buy	6,500 +4,544	+232%	+$443K	0.35%	39
2021 Q4	$211K	Sell	1,956 -3,544	-64%	-$387K	0.35%	49
2021 Q3	$602K	Buy	+5,500	New	+$571K	0.46%	33
2021 Q2	–	Sell	-3,709	Closed	-$341K	–	129
2021 Q1	$341K	Buy	+3,709	New	+$313K	0.33%	53

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

O'Neil Global Advisors's HZNP Position: Q2 2022 in Review

O'Neil Global Advisors sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q2 2022, closing a stake of 6,500 shares — an estimated $684K sold.

O'Neil Global Advisors first reported a position in HZNP in Q1 2021 and held it in 4 quarters. The position peaked at $684K in Q1 2022. 616 funds tracked by Wall St. Rank hold HZNP as of Q2 2022.

O'Neil Global Advisors reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q2 2022 after selling out during the quarter.
O'Neil Global Advisors sold 6,500 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q2 2022, an estimated $684K.
O'Neil Global Advisors first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2021 and held it in 4 quarters.
O'Neil Global Advisors's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $684K in Q1 2022.
616 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q2 2022.

Based on O'Neil Global Advisors's 13F filing for Q2 2022, filed 12 Sep 2022.